1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Karolinska Development AB (publ)

Karolinska Development AB (publ)

KDEVF
Karolinska Development AB (publ)US flagOther OTC
0.26
USD
- -
- -
68.85MMarket Cap
Karolinska Development AB (publ)
KDEVF
(Other OTC)

Recent

price

0.26

P/E

ratio

- -

div

yld

- -

ROIC.AI

2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
TTM
FRC
0.08
0.99
0.37
0.21
0.18
0.09
0.09
0.05
0.09
0.04
0.04
0.04
0.01
0.01
0.01
0.01
0.01
Revenue per Share
-0.21
-0.09
-8.91
-7.14
-3.88
-2.88
-6.77
-17.57
-3.61
2.6
0.42
3.63
-1.05
0.97
-0.34
0.02
-0.11
Basic EPS, GAAP
-0.74
-1.14
-2.69
-2.75
-2.92
-1.33
-1.97
-5.42
-0.15
-0.45
0.18
-0.08
-0.17
0.1
-0.13
-0.09
-0.1
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
28.6
26.13
12.54
2.23
6.34
-3.73
-10.42
-27.1
-27.25
-24.63
-23.12
-16.43
-7.97
-8.02
-5.81
-5.52
-5.62
Book Value per Share
59.22
65.5
40.93
29.67
38.42
28.5
22.9
4.13
0.5
3.86
4.09
12.08
4.04
5.54
4.82
4.62
4.52
Tangible Book Value per Share
28
30
38
50
55
55
55
60
60
69
72
83
198
175
257
270
270
Basic Weighted Avg Shares
2
30
14
10
10
5
5
3
5
2
3
3
3
2
2
2
2
Sales/Revenue/Turnover
-333.55
-44.4
-2,484.81
-1,497.08
-1,679.75
-1,187.31
-1,263.66
-1,488.78
-513.15
-1,381.7
-844.03
-1,151.89
-1,136.36
-1,318.53
-1,381.43
-1,369.46
-1,508.36
Operating Margin (%)
1
1
27
3
5
- -
- -
- -
- -
- -
- -
1
1
1
1
1
1
Depreciation Expense
-6
-3
-335
-354
-213
-157
-371
-1,055
-217
180
31
303
-207
171
-88
5
-29
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-248.36
-8.71
-2,407.95
-3,379.59
-2,140.72
-3,179.37
-7,385.45
-35,848.84
-4,045.37
7,288.76
992.84
8,953.22
-7,826.74
7,871.84
-3,831.39
267.43
-1,519.01
Profit Margin (%)
365
511
326
606
277
193
127
296
241
159
-344
-42
29
-42
197
86
33
Working Capital
- -
- -
2
2
- -
- -
23
349
394
379
- -
- -
- -
- -
- -
- -
- -
LT Debt
1,651
1,998
1,717
2,174
2,116
1,565
1,257
248
30
267
296
1,008
800
971
1,241
1,247
1,220
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
-6.34
-3.64
-4.16
- -
-2.9
- -
-2.21
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
-17.38
-6.34
-27.08
- -
-12.73
- -
-0.36
-2.23
Return on Capital (%)
- -
-0.33
-52.78
-121.73
-92.94
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
ST Debt
3
3
2
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
270
270
270
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
Total Current Assets
81
63
43
Cash, Cash Equivalents & STI
78
60
39
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
13
13
11
Payables & Accruals
- -
- -
- -
ST Debt
3
3
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
88.83%
53.89%
0.43%
Free Cash Flow
3.07%
-45.13%
-23.09%
Net Income, GAAP
25.93%
56.91%
-106.11%
Sales/Revenue/Turnover
-2.31%
-7.22%
-12.43%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
1
1
1
1
2
2023
1
1
- -
1
2
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.13
-0.08
-0.17
- -
-0.34
2023
-0.1
0.09
0.04
- -
0.02
2024
- -
-0.06
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Kairos Pharma, Ltd. (KAPA)
Psyence Biomedical Ltd. Warrant (PBMWW)
Alexion Pharmaceuticals, Inc. (AXP.DE)
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Trevi Therapeutics, Inc. (TRVI)
BB Biotech AG (BBZA.DE)
Business
Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is a Sweden-based investment company focused on identifying and investing in breakthrough medical innovations from the Nordic region, particularly those originating from the Karolinska Institutet and other leading universities and research institutes in Sweden, Iceland, Norway, Finland, and Denmark; the company invests in the creation and growth of biotechnology and life sciences ventures targeting life-threatening or debilitating diseases through seed, early-stage, and growth capital in areas including pharmaceutical research and development, medical research, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and services; it maintains a portfolio of eleven companies developing innovative treatments into commercial products designed to improve patient outcomes while delivering attractive returns to shareholders. Founded in 2003 and headquartered in Solna, Stockholm County, Sweden, Karolinska Development is led by an entrepreneurial team of investment professionals with a proven track record in company building and a strong global network, supporting portfolio companies with management teams, advisers, and co-investors. Recent developments include exercising a pro rata participation of SEK 7.5 million in a SEK 15 million convertible loan financing round for portfolio company BOOST Pharma in October 2025 to advance BT-101, a stem cell-based therapy for osteogenesis imperfecta (brittle bone disease), toward Phase 3 clinical development, where Karolinska Development holds a 14% ownership stake; in November 2025, BOOST Pharma raised an additional SEK 34 million tranched convertible loan from Sound Bioventures to further support BT-101's clinical progress; and the company announced a proposed rights issue of up to approximately SEK 203 million in late November 2025, subject to approval, to strengthen its financial position and investment capacity.